Pieter M. De Kesel
Ghent University Hospital
ImmunologyHeparinPartial thromboplastin timeLupus anticoagulantDanaparoidAutosomal dominant macrothrombocytopeniaDNA sequencingGeneticsBiochemistryMedicinePharmacology
What is this?
Publications 4
#1Pieter M. De Kesel (Ghent University Hospital)H-Index: 1
#2Anna Vantilborgh (Ghent University Hospital)H-Index: 6
Last. Katrien Devreese (Ghent University Hospital)H-Index: 24
view all 7 authors...
#1Tinne Monteyne (Ghent University Hospital)H-Index: 8
#2Pieter M. De Kesel (Ghent University Hospital)H-Index: 1
Last. Katrien Devreese (UGent: Ghent University)H-Index: 24
view all 3 authors...
#1Pieter M. De Kesel (Ghent University Hospital)H-Index: 1
#2Katrien Devreese (UGent: Ghent University)H-Index: 24
BACKGROUND: Direct oral anticoagulants (DOAC) interfere with lupus anticoagulant (LAC) testing. DOAC-StopTM (D-S) represents a preanalytical strategy to cope with this issue. OBJECTIVES: To assess D-S's ability to remove DOAC from plasma and overcome DOAC interference in LAC assays and to evaluate D-S's applicability in a representative patient cohort with routine LAC request. METHODS: Apixaban (30-933 ng/ml), edoxaban (31-1060 ng/ml), rivaroxaban (35-1020 ng/ml) and dabigatran (20-360 ng/ml) we...
#1Pieter M. De Kesel (Ghent University Hospital)H-Index: 1
#2Katrien Devreese (Ghent University Hospital)H-Index: 24
Background: Heparins and heparinoids interfere with functional clotting assays used for lupus anticoagulant (LAC) detection. However, current guidelines for LAC testing do not provide clear guidance on this matter. Objectives: We aimed to assess to effect of unfractionated heparin (UFH), enoxaparin, and danaparoid on LAC assays over broad anti-Xa activity ranges and to evaluate whether activated carbon (AC) is able to neutralize these effects. Methods: UFH (0.1-3.0 IU/mL), enoxaparin (0.2-2.9 IU...
2 CitationsSource